All News

The Food and Drug Administration approved the supplemental new drug application for Iclusig (ponatinib) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.

This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.

Orgovyx is the first oral drug to treat patients with advanced prostate cancer, who were previously treated with intravenous drugs that required clinic visits.

This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.

From a new study showing data that patients with cancer, especially Black patients with cancer, are at a higher risk for COVID-19 than non-cancer patients to NFL punter Rigoberto Sanchez making a speedy recovery after surgery for cancer, here’s what’s happening in the cancer space this week.

An ongoing phase 1/2 was put on hold by the Food and Drug Administration after the death of a patient with pancreatic cancer.

For multiple patients with blood cancers who would normally use Rituxan, the Food and Drug Administration has approved the biosimilar Riabni based off highly similar clinical evidence between the two drugs, potentially lowering costs for patients.

Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.

More than half of the patients with breast cancer who took part in an education-only or exercise-based intervention program remained lymphedema free 18 months following surgery to remove one or more of their lymph nodes.

Data from the trial that led to the Food and Drug Administration approval demonstrated that Margenza plus chemotherapy reduced the risk of disease progression or death in patients with metastatic HER2-positive breast cancer by 24%, compared with Herceptin plus chemotherapy.

Advancements in the diagnosis and staging of multiple myeloma continue to shape treatment decisions and improve outcomes.

In an interview with CURE®, Dr. Giada Bianchi provides patients an overview of myeloma, including symptoms and risk factors of the disease people should look out for.

After a median follow-up of 9.9 months, 38% of the trial participants experienced some degree of tumor shrinkage after receiving Opdivo in combination with Yervoy.

The complexity of multiple myeloma can make it difficult to treat, but with complexity comes more avenues for researchers to explore what treatments work best. Recently, CURE® spoke with an expert from Dana-Farber Cancer Institute on what patients can expect to see from the clinical setting.

If a patient with cancer is no longer receiving active treatment and there are no signs of active disease, an expert from The University of Texas MD Anderson Cancer Center suggests they should have a good response to the COVID-19 vaccine, but direct data on this are not yet available.

This study also found that women with higher waist circumferences had a higher risk for cancer-related and all-cause death compared with those with lower waist circumferences.

Results from this blood test may help develop informed treatment plans for pancreatic cancer and potentially help patients avoid unnecessary treatment.

On social media, in honor of the holiday season, CURE® recently asked its readers to share some of the best gifts they either given or received during their cancer treatment.

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.

A new grant program offers financial assistance for patients with mesothelioma who must travel for cancer care.

Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.

Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

The Food and Drug Administration has issued the first emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 in people 16 years old and older.

An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

From actor Jason Momoa gifting a trident to a young fan of the superhero movie “Aquaman” who is receiving treatment for an aggressive form of brain cancer, to data demonstrating the regular consumption of chili peppers is associated with lower cancer mortality rates, here’s everything happening in the cancer landscape this week.